{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:11:59Z","timestamp":1761052319544,"version":"build-2065373602"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.bcmd.2017.02.008","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T11:04:21Z","timestamp":1488366261000},"page":"13-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Letter to the Editor on Pastores et al. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease"],"prefix":"10.1016","volume":"64","author":[{"given":"Joan","family":"Keutzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gruskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2017.02.008_bb0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bcmd.2016.03.004","article-title":"Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease","volume":"59","author":"Pastores","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"year":"2015","series-title":"VPRIV\u00ae velaglucerase alfa for injection","author":"Human Genetic Therapies Inc","key":"10.1016\/j.bcmd.2017.02.008_bb0010"},{"year":"2010","series-title":"VPRIV\u00ae: NDA 022575 summary review","author":"Food and Drug Administration","key":"10.1016\/j.bcmd.2017.02.008_bb0015"},{"year":"2010","series-title":"VPRIV\u00ae: NDA 022575 statistical review(s)","author":"Food and Drug Administration","key":"10.1016\/j.bcmd.2017.02.008_bb0020"},{"year":"2010","series-title":"VPRIV\u00ae: NDA 022575 clinical pharmacology and biopharmaceutics review(s)","author":"Food and Drug Administration","key":"10.1016\/j.bcmd.2017.02.008_bb0025"},{"issue":"23","key":"10.1016\/j.bcmd.2017.02.008_bb0030","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","article-title":"Phase 1\/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience","volume":"115","author":"Zimran","year":"2010","journal-title":"Blood"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616302777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616302777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:32:44Z","timestamp":1761049964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616302777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":6,"alternative-id":["S1079979616302777"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2017.02.008","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter to the Editor on Pastores et al. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2017.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}